Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Clinical Oncology

• Publication date

  2002-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.20.3.850PMID 11821470
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biochemical markers and skeletal metastases

  2000cited by this paper
• Biochemical markers and skeletal metastases.

  2000cited by this paper
• Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases

  1999cited by this paper
• Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion

  1999cited by this paper
• Use of bone turnover marker, pyridinoline cross‐linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer

  1999cited by this paper
• Type I and Type III Collagen Metabolites as Predictors of Clinical Outcome in Epithelial Ovarian Cancer

  1999cited by this paper
• Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer.

  1999cited by this paper
• Markers of bone resorption in patients treated with pamidronate.

  1998cited by this paper
• Monitoring of multiple myeloma patients by simultaneously measuring marker substances of bone resorption and formation.

  1998cited by this paper
• Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.

  1997cited by this paper
• Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.

  1997cited by this paper
• Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease.

  1997cited by this paper
• Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.

  1996cited by this paper
• Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.

  1996cited by this paper
• Biochemical markers of bone turnover in patients with metastatic bone disease.

  1995cited by this paper
• Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer.

  1994cited by this paper
• Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma.

  1992cited by this paper
• The clinical course of bone metastases from breast cancer.

  1987cited by this paper
• The palliation of symptomatic osseous metastases final results of the study by the radiation therapy oncology group

  1982cited by this paper

• Pancreatic Cancer Progression Involves Increased Lysyl Oxidase-Mediated Collagen Cross-Links as Part of the Desmoplastic Reaction.

  2025cites this paper
• Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience

  2024cites this paper
• N-telopeptide as a potential diagnostic and prognostic marker for bone metastasis in human cancers: A meta-analysis

  2023cites this paper
• Clinical Outcomes of Switching from Zoledronic Acid to Denosumab for the Management of Severe Bone Metastasis from Hepatocellular Carcinoma: A Single-Center, Open-Label, Prospective Intervention Trial.

  2023cites this paper
• Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors

  2022cites this paper
• A Novel Radiographic Pattern Related to Poor Prognosis in Patients with Prostate Cancer with Metastatic Spinal Cord Compression

  2022cites this paper
• Bone Metastasis in Bladder Cancer

  2022cites this paper
• Comparison of metastatic castration-resistant prostate cancer in bone with other sites: clinical characteristics, molecular features and immune status

  2021cites this paper
• Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation

  2021cites this paper
• Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS)

  2021cites this paper
• Printing the Pathway Forward in Bone Metastatic Cancer Research: Applications of 3D Engineered Models and Bioprinted Scaffolds to Recapitulate the Bone–Tumor Niche

  2021cites this paper
• Biochemical markers of bone turnover in osteoporosis

  2021cites this paper
• Association between Bone Mineral Density and Bone Turnover Markers in Breast Cancer Patients and Bone-Only Metastasis

  2021cites this paper
• Current and Emerging Biomarkers Predicting Bone Metastasis Development

  2020cites this paper
• Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma

  2020cites this paper
• Application of “omics” sciences to the prediction of bone metastases from breast cancer: State of the art

  2020cites this paper
• Comparison of bone biomechanical properties after bone marrow mesenchymal stem cell or alendronate treatment in an osteoporotic animal model

  2019cites this paper
• The Bone Extracellular Matrix as an Ideal Milieu for Cancer Cell Metastases

  2019cites this paper
• Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study

  2019cites this paper
• New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions

  2019cites this paper
• Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223

  2018cites this paper
• Molecular heterogeneity of prostate cancer bone metastasis

  2018cites this paper
• Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity

  2018cites this paper
• Prostate cancer and bone cell interactions : implications for metastatic growth and therapy

  2017cites this paper
• Matrix Metalloproteinases in Bone Resorption, Remodeling, and Repair.

  2017cites this paper
• Clinical outcome and prognostic factors in hepatocellular carcinoma patients with bone metastases medicated with zoledronic acid

  2017cites this paper
• Physical training, inflammation and bone integrity in elite female rowers

  2017cites this paper
• Bone metabolism markers: Indicators of loading dose intravenous ibandronate treatment for bone metastases from breast cancer

  2017cites this paper
• Effects of Yishengukang decoction on expression of bone-specific alkaline phosphatase, carboxyterminal propeptide of type Ⅰ procollagen, and carboxyterminal cross-linked telepeptide of type Ⅰ collagen in malignant tumor patients with bone metastasis.

  2017cites this paper
• Markers of Bone Turnover in Bone Metastasis from Prostate Cancer

  2017cites this paper
• Approaches for Assessment of Response of Bone Metastases to Therapies

  2017cites this paper
• Elevation of serum CEA and CA15-3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients.

  2017cites this paper
• Bone metastases in patients with small cell lung carcinoma: rate of development, early versus late onset, modality of treatment, and their impact on survival. A single-institution retrospective cohort study

  2016cites this paper
• Diagnostic Applications of Nuclear Medicine: Prostatic Cancer

  2016cites this paper
• Serum cross-linked N-telopeptide of type I collagen for the diagnosis of bone metastases from solid tumours in the Chinese population: Meta-analysis

  2016cites this paper
• Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622

  2016cites this paper
• N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.

  2016cites this paper
• Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons

  2016cites this paper
• Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents

  2016cites this paper
• The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club

  2016cites this paper
• Use of urinary markers in cancer setting: A literature review

  2015cites this paper
• The influence of menopausal status on bone turnover and disease control in breast cancer patients with metastatic bone disease treated with chemotherapy plus zoledronic acid: an exploratory retrospective cohort study

  2015cites this paper
• Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.

  2015cites this paper
• Effect of re-irradiation for painful bone metastases on urinary markers of osteoclast activity (NCIC CTG SC.20U).

  2015cites this paper
• Bone remodeling markers and bone metastases: From cancer research to clinical implications.

  2015cites this paper
• Prospective Evaluation of Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma

  2015cites this paper
• Phytochemical Investigations and Antioxidant Activity of Green Tea

  2015cites this paper
• Bone metastases in lung cancer. Potential novel approaches to therapy.

  2015cites this paper
• Chapter 12 – Bone remodeling markers and bone cancer

  2015cites this paper
• Salivary Biomarkers Associated With Bone Deterioration in Patients With Medication-Related Osteonecrosis of the Jaws.

  2015cites this paper
• Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors

  2015cites this paper
• Biochemical Markers of Bone Metabolism in Breast Cancer

  2014cites this paper
• The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review

  2014cites this paper
• Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial.

  2014cites this paper
• Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials

  2014cites this paper
• Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study).

  2014cites this paper
• Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.

  2013cites this paper
• RANKL/RANK/MMP-1 Molecular Triad Contributes to the Metastatic Phenotype of Breast and Prostate Cancer Cells In Vitro

  2013cites this paper
• Denosumab in breast cancer treatment.

  2013cites this paper
• Biochemical Markers of Bone Turnover in Osteoporosis

  2013cites this paper
• Randomized Feasibility Study of De-escalated (Every 12 wk) Versus Standard (Every 3 to 4 wk) Intravenous Pamidronate in Women With Low-risk Bone Metastases From Breast Cancer

  2013cites this paper
• miR-326 associates with biochemical markers of bone turnover in lung cancer bone metastasis.

  2013cites this paper
• New and emerging therapies for bone metastases in genitourinary cancers.

  2013cites this paper
• Denosumab for the treatment of bone metastases in advanced breast cancer.

  2013cites this paper
• Bone resorption markers and dual-energy x-ray absorptiometry in dogs with avascular necrosis, degenerative joint disease, and trauma of the coxofemoral joint.

  2012cites this paper
• RANKL Inhibition: Clinical Data

  2012cites this paper
• Denosumab Dose Selection for Patients with Bone Metastases from Solid Tumors

  2012cites this paper
• The role of the bone microenvironment in skeletal metastasis

  2012cites this paper
• Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer.

  2012cites this paper
• Diagnostic and prognostic use of bone turnover markers.

  2012cites this paper
• Treatment-Induced Bone Loss and Fractures in Cancer Patients Undergoing Hormone Ablation Therapy: Efficacy and Safety of Denosumab

  2012cites this paper
• Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases.

  2012cites this paper
• Principles of Osteoimmunology

  2012cites this paper
• Bone metastases detection by circulating biomarkers: OPG and RANK-L.

  2011cites this paper
• Consensus on the utility of bone markers in the malignant bone disease setting.

  2011cites this paper
• Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data.

  2011cites this paper
• Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results.

  2011cites this paper
• Can we predict who's at risk for developing bone metastases in breast cancer?

  2011cites this paper
• Serum N-Terminal Propeptide of Collagen Type I is Associated with the Number of Bone Metastases in Breast and Prostate Cancer and Correlates to Other Bone Related Markers

  2011cites this paper
• Bone turnover markers: Tools for prognosis and monitoring response to bisphosphonates?

  2011cites this paper
• A phase I study of zoledronic acid and low‐dose cyclophosphamide in recurrent/refractory neuroblastoma: A new approaches to neuroblastoma therapy (NANT) study

  2011cites this paper
• Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases.

  2011cites this paper
• Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid

  2011cites this paper
• Bone turnover markers in HIV disease.

  2011cites this paper
• Denosumab as Bone Modifying Therapy in Solid Tumors

  2011cites this paper
• Bisphosphonates: from preclinical evidence to survival data in the oncologic setting

  2011cites this paper
• Role of OPG-RANK-RANKL pathway in the pathophysiology, diagnosis and therapeutic follow-up of metastatic bone disease

  2011cites this paper
• Collagenous and non-collagenous biochemical markers of bone metastases from prostate cancer.

  2010cites this paper
• Bone Remodeling Markers and Bone Cancer

  2010cites this paper
• Clinical and imaging correlations of bone turnover markers in prostate cancer patients with bone only metastases

  2010cites this paper
• The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases.

  2010cites this paper
• Comparative Review of Denosumab Versus Zoledronic Acid for the Reduction or Delay of Serious Complications Associated with Bone Metastases of Breast Cancer

  2010cites this paper
• N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases

  2010cites this paper
• Evaluation of the safety, pharmacokinetics and treatment effects of an ανβ3 integrin inhibitor on bone turnover and disease activity in men with hormone‐refractory prostate cancer and bone metastases

  2010cites this paper
• Bone-marker levels in patients with prostate cancer: potential correlations with outcomes

  2010cites this paper
• 骨代谢标志物ICTP、BAP对肺癌骨转移的诊断意义

  2010cites this paper
• Incidence of acute phase adverse events following denosumab or intravenous bisphosphonates: results from a randomized, controlled phase II study in patients with breast cancer and bone metastases

  2010cites this paper
• Future directions of bone-targeted therapy for metastatic breast cancer

  2010cites this paper
• Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting.

  2010cites this paper
• Prevention and treatment of bone metastases.

  2010cites this paper